<DOC>
	<DOCNO>NCT01532362</DOCNO>
	<brief_summary>The primary objective trial determine biological ability apricoxib decrease T reg cell peripheral blood tumor infiltrate lymphocyte subject compare subject early stage Non-small Cell Lung Cancer ( NSCLC ) . The secondary objective determine efficacy apricoxib inhibit CD4+CD25+ T reg FOXP3 function exploration COX-2 dependent biomarkers apoptosis resistance , angiogenesis , invasion , immunity .</brief_summary>
	<brief_title>Evaluation Apricoxib ( Selective Cyclooxygenase 2 Inhibition ) Modulating T Regulatory Cells Patients With Early Stage Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Adults age 18 capable give informed consent . Radiographic finding suspicious primary lung cancer pathologically confirm NSCLC surgically resectable radiographically early stage ( stage I II ) . ECOG performance status 0 , 1 , 2 ( see Appendix A ) . Ineligible refuse preoperative chemotherapy chemoradiation therapy Normal renal function ( define serum creatinine ≤ 2 mg/dl creatinine clearance ≥ 60 ml/min/1.73m2 ) . Normal liver function ( defined total bilirubin ≤ 1.5 x ULN , SGOT &amp; SGPT ≤ 2.5 xULN ) . Negative pregnancy test prior initiation treatment adequate contraception throughout treatment . Preoperative pulmonary function test ( PFT ) FEV1 D LCO ≥ 60 % predict postoperative FEV1 DLCO ≥ 40 % base quantitative lung perfusion scan Must able come anticoagulant normal coagulation study ( PTT &lt; 40 second INR &lt; 1.4 ) prior plan surgery . For subject COX2 inhibitor NSAIDS prior study initiation , cessation drug 1 week prior Apricoxib administration require study enrollment . Radiation therapy , chemotherapy , noncytotoxic investigational agent , corticosteroid within 4 week initiate treatment . Comorbid disease medical condition would impair ability subject receive comply study protocol . Hypersensitivity apricoxib , sulfonamide , aspirin , NSAIDS reagent use study . Previous history gastrointestinal ulceration , bleeding , perforation . Required concurrent use COX2 inhibitor NSAIDS Apricoxib administration . Chronic concurrent use steroid ( topical steroid acceptable medically indicate ) . Pregnant nursing woman . Evidence NYHA class III great cardiac disease . History myocardial infarction , stroke , ventricular arrhythmia , symptomatic conduction abnormality within 12 month initiate treatment . History heart surgery coronary artery disease . Known HIV infection AIDS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>